Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients

International Journal of Urology

Volumn 14, Issue 11, 2007, Pages 995-999

  Denzinger, Stefan ^a   Otto, Wolfgang ^a   Fritsche, Hans Martin ^a   Roessler, Wolfgang ^a   Wieland, Wolf F ^a   Hartmann, Arndt ^a   Burger, Maximilian ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Cancer specific survival; Progression; Recurrence rate; Risk factor; T1G3 bladder cancer

Indexed keywords

ADULT; AGED; ARTICLE; BCG VACCINATION; BLADDER CANCER; BLADDER IRRIGATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARCINOMA IN SITU; CONTROLLED STUDY; CYSTOSCOPY; CYTOLOGY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIVARIATE ANALYSIS; MUSCLE DISEASE; PRIORITY JOURNAL; RECURRENCE RISK; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; TUMOR VOLUME;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA IN SITU; CYSTECTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; URINARY BLADDER NEOPLASMS; UROLOGIC SURGICAL PROCEDURES;

EID: 35448943642     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2007.01890.x     Document Type: Article

References (20)

1. Soloway MS, Sofer M, Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J. Urol. 2002 167 : 1573 83.
2. Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study. J. Urol. 2002 163 : 1124 9.
3. Cheng L, Weaver AL, Neumann RM, Scherer BG, Bostwick DG. Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: A new proposal. Cancer 1999 86 : 1035 43.
4. Sriprasad SI, Hopster D, Muir GH et al. The biological characteristics of T1G3 bladder tumours are the same as muscle invasive cancer: A study of cell proliferation and molecular markers of aggressiveness. J. Urol. 2001 165 : 192 3.
5. Orsola A, Trias I, Raventós CX et al. Initial high-grade T1 urothelial cell carcinoma: Feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur. Urol. 2005 48 : 231 8.
6. Schips L, Augustin H, Zigeuner RE et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 2002 59 : 220 3.
7. Schwaibold HE, Sivalingam S, May F, Hartung R. The value of a second transurethral resection for T1 bladder cancer. BJU Int. 2006 97 : 1199 201.
8. Thalmann GN, Markwalder R, Shahin O, Burkhard FC, Hochreiter WW, Studer UE. Primary T1G3 bladder cancer: Organ preserving approach or immediate cystectomy? J. Urol. 2004 172 : 70 5.
9. Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: Recurrence, progression and survival. J. Urol. 2003 169 : 96 100.
10. Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J. Urol. 2001 166 : 1296 9.
11. Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1054 patients. J. Clin. Oncol. 2001 19 : 666 75.
12. Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 2006 49 : 466 71.
13. Hurle R, Losa A, Manzetti A, Lembo A. Intravesical bacillus Calmette-Guerin in stage T1, grade 3 bladder cancer therapy: A 7-year follow-up. Urology 1999 54 : 258 63.
14. Lebret T, Gaudez F, Herve JM, Barre P, Lugagne PM, Botto H. Low-dose BCG instillations in the treatment of Stage T1 Grade 3 bladder tumours: Recurrence, progression and success. Eur. Urol. 1998 34 : 67 72.
15. Brake M, Loertzer H, Horsch R, Keller H. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J. Urol. 2000 163 : 1697 701.
16. Herr HW, Donat SM. A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int. 2006 97 : 1194 8.
17. Herr HW. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J. Urol. 2005 174 : 2134 7.
18. Pansadoro V, Emiliozzi P, de Paula F, Scarpone P, Pansadoro A, Sternberg CN. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology 2002 59 : 227 31.
19. Maranchie JK, Bouyounes BT, Zhang PL, O'Donnell MA, Summerhayes IC, DeWolf WC. Clinical and pathological characteristics of micropapillary transitional cell carcinoma: A highly aggressive variant. J. Urol. 2000 163 : 748 51.
20. Kamat AM, Gee JR, Dinney CP et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J. Urol. 2006 175 : 881 5.